News archive

B cells are immune cells that help fight infection, but when they go rogue, they can drive autoimmune diseases like Sjögren's. Here's what to know.

For more than three decades, Novartis has been committed to the fight against malaria, one of the world's deadliest diseases. Fortune has now recognized that work by naming our malaria program to its 2026 Change The World list.

Millions of people around the world continue to face barriers to prevention, diagnosis and treatment for chronic diseases such as heart disease and cancer. To help address these gaps, Novartis is scaling its community health programs from 11 to more than 30 countries by 2030, working alongside local partners to connect more people to care.

Learn more about HeART, a five-year partnership between Novartis and Meharry Medical College focused on improving cardiovascular health in three US cities. Liz McGee, Global Head of Inclusive Health Accelerators, Novartis, reflects on how health starts with listening to the people closest to the challenge. 

Breast cancer doesn’t stop when treatment ends. For many, its most enduring challenges remain under recognized and undiscussed. Through Letters Between Us  and ongoing community engagement, Novartis is sharing real patient stories to highlight the power of community connection and inspire strength in others.

In Letters Between Us, people impacted by breast cancer wrote letters about what they had learned since a breast cancer diagnosis. Learn more about their experience at Camp Breastie, a community-based organization.

Learn how fatigue, emotional wellbeing, and shared decision-making shape patient-centered care for those living with immune thrombocytopenia (ITP).

For many people living with hidradenitis suppurativa (HS), the hardest part isn’t finding treatment—it’s getting a timely diagnosis. A new collaboration between Novartis and the American Academy of Dermatology combines real-world data and AI tools to provide patients with hope.